North America Non-Small Cell Lung Cancer Diagnostics Market is growing with factors such as the usage of artificial intelligence and machine learning to improve the diagnostics procedures coupled with rise in number of geriatric population that is more susceptible to non-small cell lung cancer. Increasing demand for non-small cell lung cancer diagnostics instruments, kits and others to diagnose patients act as a major factor for the growth of the market. Favorable product launch for the non-small cell lung cancer diagnostics for healthcare have also given a boom to the North America non-small cell lung cancer diagnostics market.
Technological advancements have propelled the demand of the market. However, challenges associated with brand equity and the high cost of instrumentation has decreased the demand of the market.
North America Non-Small Cell Lung Cancer Diagnostics Market Scenario
According to Data Bridge Market Research, the market for North America non-small cell lung cancer diagnostics in North America has the highest market share. Market leader is Abbott, which accounts an estimated market share of approximately 22.00% in the North America market. The company has gained outstanding sale by launching products of non-small cell lung cancer diagnostics.
- In October 2020, Abbott expanded its business by launching companion diagnostics, Vysis ALK Break Apart FISH Probe Kit in Europe, to diagnose non-small cell lung cancer patients eligible for XALKORI treatment
Trends Impacting the Market
Now the question is which other regions Abbott, Hoffmann-La Roche Ltd, and Quest Diagnostics Incorporated are targeting? Data Bridge Market Research has forecasted a large growth in Asia Pacific non-small cell lung cancer diagnostics market and the market leaders are targeting India and Philippines to be their next pocket revenue for 2021.
The non-small cell lung cancer diagnostics market is becoming more competitive with companies like Abbott, Hoffmann-La Roche Ltd, Quest Diagnostics Incorporated. These are the top dominating companies in non-small cell lung cancer diagnostics market and have launched new non-small cell lung cancer diagnostics products in the market. The data bridge market research new reports highlight the major growth factors and opportunities in the North America non-small cell lung cancer diagnostics market.
For more analysis on the North America non-small cell lung cancer diagnostics market request for a briefing with our analysts https://www.databridgemarketresearch.com/de/speak-to-analyst/?dbmr=north-america-non-small-cell-lung-cancer-diagnostics-market
Non-Small Cell Lung Cancer Diagnostics Market Developments
- In June 2020, F. Hoffmann-La Roche Ltd launched automated digitalpathology algorithm, uPath PD-L1 (SP263) image analysis to diagnose non-small cell lung cancer (NSCLC) and improve the speed and accuracy of diagnosis treatment. This new launch of the algorithm helped the pathologiest to assess the disease more effectively.
- In June 2021, Quest Diagnostics Incorporated partnered with Biocept to offer its target selector next-generation sequencing (NGS)-based liquid biopsy targeted lung cancer panel to the customers and also use Biocept’s less invasive, lab-developed assay to conduct genomic profiling in advanced NSCLC patients. This partnership helped the company offer their product to a large consumer base and develop more advanced technology.
Scope of the Non-Small Cell Lung Cancer Diagnostics Market
All country based analysis of the North America non-small cell lung cancer diagnostics market is further analysed based on maximum granularity into further segmentation. On the basis of cancer type, the North America non-small cell lung cancer diagnostics market is segmented into lung adenocarcinoma (LUAD), lung squamous cellcarcinoma (LUSC), large cell carcinoma and others. On the basis of products, the North America non-small cell lung cancer diagnostics market is segmented into reagents & kits, instruments and services & softwares. Reagents & kits are further segmented into lung cancer assay kit, sample preparation kit, mutation kit, solid tumor kit, extraction kit and others. On the basis of test, the North America non-small cell lung cancer diagnostics market is segmented imaging test, molecular test, biopsy, sputum cytology, thoracentesis, immunohistochemistry and others. On the basis of end user, the North America non-small cell lung cancer diagnostics market is segmented into hospital, clinical laboratories, academics and institutes and research centers.
To know more about the study https://www.databridgemarketresearch.com/de/reports/north-america-non-small-cell-lung-cancer-diagnostics-market
Key Pointers Covered in Non-Small Cell Lung Cancer Diagnostics Market Industry Trends and Forecast to 2028
- Market Size
- Top to Bottom Market Analysis
- Recent Developments for Market Competitors
- Recent Market Value for Different Countries
- Market value and over view of Non-small cell lung cancer diagnostics market
- Company profiling of top eight players of Non-small cell lung cancer diagnostics market
Key Market Competitors Covered in the Report
- Abbott
- F. Hoffmann-La Roche Ltd
- Agilent Technologies, Inc.
- QIAGEN
- Thermo Fisher Scientific Inc.
- Quest Diagnostics Incorporated
- NeoGenomics Laboratories, Inc.
- NanoString
- Janssen Pharmaceutical NV
- Inivata Ltd
- bioMérieux SA
- Biotheranostics
- OncoCyte Corporation Inc.
- GENERAL ELECTRIC COMPANY
- Eckert & Ziegler
- DrLal PathLabs
- RIVERAIN TECHNOLOGIES
- PlexBio Co.,Ltd
- Oncimmune
- Biodesix
Above are the key players covered in the report, to know about more and exhaustive list of non-small cell lung cancer diagnostics companies’, contact us https://www.databridgemarketresearch.com/de/toc/?dbmr=north-america-non-small-cell-lung-cancer-diagnostics-market
Research Methodology: North America Non-Small Cell Lung Cancer Diagnostics Market
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include vendor positioning grid, market time line analysis, market overview and guide, company positioning grid, company market share analysis, standards of measurement, top to bottom analysis and vendor share analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Primary Respondents
- Demand Side: Manufacturer, Researcher, Hospitals
- Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.
Related Reports
- North America Non-Small Cell Lung Cancer Market - Industry Trends and Forecast to 2028
- North America Lung Cancer Surgery Market - Industry Trends and Forecast to 2028.
- North America Lung Cancer Diagnostics Market - Industry Trends and Forecast to 2027
- North America Lung Cancer Therapeutics Market - Industry Trends and Forecast to 2026
Browse in Healthcare Category Related Reports@ https://www.databridgemarketresearch.com/de/report-category/healthcare/
